3.88

0.00% 0.00

Relmada Therapeutics Inc (RLMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Relmada Therapeutics Inc stock is traded at $3.88, with a volume of 847.06K. It is up +0.00% in the last 24 hours and up +101.04% over the past month. Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Previous Close:

$3.88

Open:

$3.542

24h Volume:

847.06K

Relative Volume:

0.73

Market Cap:

$135.92M

Revenue:

Net Income/Loss:

$-98.79M

P/E Ratio:

-1.1865

EPS:

-3.27

Net Cash Flow:

$-51.66M

1W Performance:

+46.42%

1M Performance:

+101.04%

6M Performance:

+802.33%

1Y Performance:

+22.78%

1-Day Range:

$3.31

$4.10

1-Week Range:

$2.65

$4.28

52-Week Range:

$0.2404

$4.28

Relmada Therapeutics Inc Stock (RLMD) Company Profile

Name

Relmada Therapeutics Inc

Sector

Healthcare (1129)

Industry

Biotechnology (618)

Phone

646 876 3459

Address

2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY

Employee

Twitter

@relmada

Next Earnings Date

2025-03-25

Latest SEC Filings

RLMD's Discussions on Twitter

Compare RLMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RLMD	3.03	0	0	0	0	0.00
MOBBW Mobilicom Limited Warrants	2.15	2.85B	0	0	0	0.00
GOODO Gladstone Commercial Corporation	19.70	372.90M	0	0	0	0.00
SHMD Schmid Group N V	5.765	211.87M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	0.2139	485.32M	2.07B	-1.42B	-1.37B	-0.6765
DAVEW Dave Inc	0.99	0	0	0	0	0.00

Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Jun-05-24	Downgrade	Goldman	Neutral → Sell
Oct-14-22	Downgrade	Goldman	Buy → Neutral
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Truist	Buy → Hold
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform
Nov-18-21	Initiated	Mizuho	Buy
May-20-21	Resumed	Goldman	Buy
Oct-28-20	Downgrade	Goldman	Buy → Neutral
Jul-14-20	Initiated	Oppenheimer	Outperform
May-04-20	Initiated	SunTrust	Buy
Apr-21-20	Initiated	Goldman	Buy
Jan-27-20	Initiated	Jefferies	Buy
Jan-10-20	Initiated	SVB Leerink	Outperform
Dec-16-19	Initiated	Guggenheim	Buy

View All

Relmada Therapeutics Inc Stock (RLMD) Latest News

08:23 AM

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2025 Earnings Call Transcript - Insider Monkey

08:23 AM

04:57 AM

Is Relmada Therapeutics Inc. stock ready for a breakoutSell Signal & Community Consensus Trade Alerts - newser.com

04:57 AM

02:22 AM

Why Relmada Therapeutics Inc. (4E2) stock stays resilientProduct Launch & Safe Entry Point Alerts - newser.com

02:22 AM

01:55 AM

Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing - MSN

01:55 AM

01:46 AM

What valuation ratios show for Relmada Therapeutics Inc. (4E2) stockBear Alert & Weekly High Potential Stock Alerts - newser.com

01:46 AM

12:10 PM